Key Takeaways
- Evogene Ltd. expands partnership with Google Cloud to integrate AI Agents into ChemPass AI™
- Collaboration leverages Google Cloud’s Vertex AI platform to enhance small-molecule discovery
- AI Agents designed to automate complex scientific workflows and accelerate design cycles
- Builds on October 2024 milestone involving a generative AI foundation model
- Expansion supports pharmaceutical and agricultural small-molecule development
Evogene Ltd. Advances ChemPass AI™ with Google Cloud AI Agents
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a computational chemistry company focused on AI-driven small-molecule design for pharmaceutical and agricultural applications, has announced an expanded phase of its collaboration with Google Cloud.
Under the new phase, Evogene Ltd. will develop and integrate advanced AI Agents into its ChemPass AI™ platform using Google Cloud’s Vertex AI infrastructure. The initiative aims to enhance the speed, precision, and efficiency of identifying and optimizing small molecules for drug and ag-chemical development.
This marks the second major milestone in the partnership between Evogene Ltd. and Google Cloud. In October 2024, the companies announced the successful development of a generative AI foundation model that now serves as a core component of ChemPass AI™.
AI Agents to Automate Discovery Workflows
The expanded collaboration introduces AI Agents—autonomous artificial intelligence systems capable of planning, reasoning, and executing multi-step scientific workflows. When integrated into ChemPass AI™, these agents are designed to automate discovery processes, enable large-scale parallel molecular exploration, and shorten design–make–test–analyze cycles.
According to Evogene Ltd., the integration is expected to improve accuracy and increase the success rate of designing commercially viable small-molecule candidates that meet stringent development criteria.
Boaz Maoz, Managing Director of Google Cloud Israel, stated: “This expanded collaboration with Evogene demonstrates the power of integrating cutting-edge artificial intelligence into scientific research. By leveraging our technology to deploy advanced AI agents, we are enabling Evogene to automate and scale their complex discovery workflows.”
Evogene Ltd. Targets Scalable Molecular Design
Evogene Ltd. indicated that the enhanced ChemPass AI™ platform will support multiple discovery programs running in parallel, with potential improvements to operational speed and cost efficiency.
Ofer Haviv, President and CEO of Evogene Ltd., said: “The integration of AI agents into ChemPass AI™ is expected to improve our speed, cost structure, and ability to run multiple discovery programs in parallel. We are also excited about the potential to make parts of our real-world innovation tools globally accessible through Google Cloud Marketplace.”
The company stated that the collaboration reflects a shift toward more autonomous discovery processes as it continues to expand its molecular design capabilities for pharmaceutical and agricultural markets.
4 Comments